The mutational landscape of colorectal cancer (CRC) does not enable predictions to be
made about the survival of patients or their response to therapy. Instead, studying the …

Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Background In order to correctly decode phenotypic information from RNA-sequencing
(RNA-seq) data, careful selection of the RNA-seq quantification measure is critical for inter …

Abstract Around 30–40% of patients with colorectal cancer (CRC) undergoing curative
resection of the primary tumour will develop metastases in the subsequent years. Therapies …

Prostate cancer shows remarkable clinical heterogeneity, which manifests in spatial and
clonal genomic diversity. By contrast, the transcriptomic heterogeneity of prostate tumours is …

Immunotherapy for metastatic colorectal cancer is effective only for mismatch repair-deficient
tumors with high microsatellite instability that demonstrate immune infiltration, suggesting …

Background For virtually every patient with colorectal cancer (CRC), hematoxylin–eosin
(HE)–stained tissue slides are available. These images contain quantitative information …

Transforming growth factor (TGF)-β is a crucial enforcer of immune homeostasis and
tolerance, inhibiting the expansion and function of many components of the immune system …

The tumor microenvironment has been identified as one of the driving factors of tumor
progression and invasion. Inside this microenvironment, cancer‐associated fibroblasts …